Loading
hVIVO plc Stock: price and insider trades · United Kingdom
No insider purchase over the last 90 days. The latest was filed 02 Jun 2025.
hVIVO plc: what insiders have been doing
This page follows insider dealings at hVIVO plc as filed with RNS (LSE). 1 insider has disclosed 1 filing since 18 October 2025.
There is no open-market purchase to report; the filings show 1 sale by 1 insider. The amount is not disclosed for 1 filing.
Compared with its exchange (833 companies, median 6 filings), a count of 1 filing is below the norm. Since 2025, the database holds 2 purchases and 2 sales by insiders of the company.
Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
These figures are compiled from regulatory filings published by RNS (LSE). They describe what insiders did and are not a recommendation.
Insider Decl.
4
Thresholds
n/a
Buy Volume
n/a
2 ops. · all time
Sell Volume
n/a
2 ops. · all time
Who traded when
BuySaleBrendan Buckley1 sale
Stephen Pinkerton1 buy
Y amin 'Mo' Khan1 sale
Yamin Mo Khan1 buy
Since the insiders bought
- -19.7%Entry £0.10 · Close at T+365 £0.08
- -19.7%Entry £0.10 · Close at T+365 £0.08
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 22,498 of 24,148 companies
18.5
score / 100
Value7
Quality30
FCF yld-35%
Earn yld-13%
EV/EBITDA50.3x
ROE-14%
Gross mgn77%
Net mgn-13%
Debt/EBITDA12.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
£0.07
Analyst consensus
8 analysts1.50/5
£0.10Target £0.17(+162%)£29.00
Income statement
Revenue£46.8M
Gross profit£35.9M77% margin
EBITDA£1.2M3% margin
Net income-£6M-12.1% margin
Valuation
PER (forward)-3815.0x
P/Book117.9x
Beta1.71
Balance sheet & cash
Market cap£45.4M
Total debt£14.8M
Free Cash Flow-£15.8M
Debt / Equity39%
Profitability & ownership
ROE-14.5%
ROA-2.5%
% insiders3.2%
% institutions30.8%
Last declaration on 24 April 2026
Declarations4 total
0London Stock Exchange, AIM Market (XLON)ISIN GB00B9275X97RNS:c0230947-d61c-4784-8414-77b4a3b88c36
0London Stock Exchange, AIM Market (XLON)ISIN GB00B9275X97RNS:5676651-1
Canonical exit: 28 Aug 2025 (T+90)
0London Stock Exchange, AIM Market (XLON)ISIN GB00B9275X97RNS:5676651-0
Canonical exit: 28 Aug 2025 (T+90)
0Option exercise: Outside a trading venue Sale: London Stock Exchange, AIM Market (XLON)ISIN GB00B9275X97RNS:5564770
4 of 4 declarations
About hVIVO plc
hVIVO plc is a UK-based company focused on developing treatments for respiratory and infectious diseases. It specializes in clinical trials and human challenge studies.
